Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Author(s): Shahzad Khan* and Sahibzada T. Rasool

DOI: 10.2174/1871530320999200831171748

DownloadDownload PDF Flyer Cite As
Current Use of Cardiac Biomarkers in Various Heart Conditions

Page: [980 - 993] Pages: 14

  • * (Excluding Mailing and Handling)

Abstract

Biomarkers are increasingly recognized to have significant clinical value in early identification and progression of various cardiovascular diseases. There are many heart conditions, such as congestive heart failure (CHF), ischemic heart diseases (IHD), and diabetic cardiomyopathy (DCM), and cardiac remodeling, in which the severity of the cardiac pathology can be mirrored through these cardiac biomarkers. From the emergency department (ED) evaluation of acute coronary syndromes (ACS) or suspected acute myocardial infarction (AMI) with cardiac marker Troponin to the diagnosis of chronic conditions like Heart Failure (HF) with natriuretic peptides, like B-type natriuretic peptide (BNP), N-terminal pro-B- type natriuretic peptide (Nt-proBNP) and mid regional pro-atrial natriuretic peptide (MR- proANP), their use is continuously increasing. Their clinical importance has led to the discovery of newer biomarkers, such as the soluble source of tumorigenicity 2 (sST2), galectin-3 (Gal-3), growth differentiation factor-15 (GDF-15), and various micro ribonucleic acids (miRNAs). Since cardiac pathophysiology involves a complex interplay between inflammatory, genetic, neurohormonal, and biochemical levels, these biomarkers could be enzymes, hormones, and biologic substances showing cardiac injury, stress, and malfunction. Therefore, multi-marker approaches with different combinations of novel cardiac biomarkers, and continual assessment of cardiac biomarkers are likely to improve cardiac risk prediction, stratification, and overall patient wellbeing. On the other hand, these biomarkers may reflect coexisting or isolated disease processes in different organ systems other than the cardiovascular system. Therefore, knowledge of cardiac biomarkers is imperative. In this article, we have reviewed the role of cardiac biomarkers and their use in the diagnosis and prognosis of various cardiovascular diseases from different investigations conducted in recent years.

Keywords: Biomarker, BNP, troponin, heart failure, myocardial infarction, cardiovascular disease.

[1]
Ponikowski, P.; Voors, A.A.; Anker, S.D.; Bueno, H.; Cleland, J.G.; Coats, A.J.; Falk, V.; González-Juanatey, J.R.; Harjola, V.P.; Jankowska, E.A.; Jessup, M.; Linde, C.; Nihoyannopoulos, P.; Parissis, J.T.; Pieske, B.; Riley, J.P.; Rosano, G.M.; Ruilope, L.M.; Ruschitzka, F.; Rutten, F.H.; van der Meer, P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail., 2016, 18(8), 891-975.
[http://dx.doi.org/10.1002/ejhf.592] [PMID: 27207191]
[2]
Owan, T.E.; Hodge, D.O.; Herges, R.M.; Jacobsen, S.J.; Roger, V.L.; Redfield, M.M. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N. Engl. J. Med., 2006, 355(3), 251-259.
[http://dx.doi.org/10.1056/NEJMoa052256] [PMID: 16855265]
[3]
Magnussen, C.; Blankenberg, S. Biomarkers for heart failure: small molecules with high clinical relevance. J. Intern. Med., 2018, 283(6), 530-543.
[http://dx.doi.org/10.1111/joim.12756] [PMID: 29682806]
[4]
Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther., 2001, 69(3), 89-95.
[http://dx.doi.org/10.1067/mcp.2001.113989] [PMID: 11240971]
[5]
Yasue, H.; Yoshimura, M.; Sumida, H.; Kikuta, K.; Kugiyama, K.; Jougasaki, M.; Ogawa, H.; Okumura, K.; Mukoyama, M.; Nakao, K. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation, 1994, 90(1), 195-203.
[http://dx.doi.org/10.1161/01.CIR.90.1.195] [PMID: 8025996]
[6]
Iwanaga, Y.; Nishi, I.; Furuichi, S.; Noguchi, T.; Sase, K.; Kihara, Y.; Goto, Y.; Nonogi, H. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. J. Am. Coll. Cardiol., 2006, 47(4), 742-748.
[http://dx.doi.org/10.1016/j.jacc.2005.11.030] [PMID: 16487838]
[7]
Wang, T.J.; Larson, M.G.; Levy, D.; Benjamin, E.J.; Leip, E.P.; Omland, T.; Wolf, P.A.; Vasan, R.S. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N. Engl. J. Med., 2004, 350(7), 655-663.
[http://dx.doi.org/10.1056/NEJMoa031994] [PMID: 14960742]
[8]
Maisel, A.; Mueller, C.; Adams, K., Jr; Anker, S.D.; Aspromonte, N.; Cleland, J.G.; Cohen-Solal, A.; Dahlstrom, U.; DeMaria, A.; Di Somma, S.; Filippatos, G.S.; Fonarow, G.C.; Jourdain, P.; Komajda, M.; Liu, P.P.; McDonagh, T.; McDonald, K.; Mebazaa, A.; Nieminen, M.S.; Peacock, W.F.; Tubaro, M.; Valle, R.; Vanderhyden, M.; Yancy, C.W.; Zannad, F.; Braunwald, E. State of the art: using natriuretic peptide levels in clinical practice. Eur. J. Heart Fail., 2008, 10(9), 824-839.
[http://dx.doi.org/10.1016/j.ejheart.2008.07.014] [PMID: 18760965]
[9]
Maisel, A.S.; Krishnaswamy, P.; Nowak, R.M.; McCord, J.; Hollander, J.E.; Duc, P.; Omland, T.; Storrow, A.B.; Abraham, W.T.; Wu, A.H.; Clopton, P.; Steg, P.G.; Westheim, A.; Knudsen, C.W.; Perez, A.; Kazanegra, R.; Herrmann, H.C.; McCullough, P.A. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N. Engl. J. Med., 2002, 347(3), 161-167.
[http://dx.doi.org/10.1056/NEJMoa020233] [PMID: 12124404]
[10]
Chow, S.L.; Maisel, A.S.; Anand, I.; Bozkurt, B.; de Boer, R.A.; Felker, G.M.; Fonarow, G.C.; Greenberg, B.; Januzzi, J.L., Jr; Kiernan, M.S.; Liu, P.P.; Wang, T.J.; Yancy, C.W.; Zile, M.R. Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. Circulation, 2017, 135(22), e1054-e1091.
[http://dx.doi.org/10.1161/CIR.0000000000000490] [PMID: 28446515]
[11]
Nellessen, U.; Zingel, M.; Hecker, H.; Bahnsen, J.; Borschke, D. Effects of radiation therapy on myocardial cell integrity and pump function: which role for cardiac biomarkers? Chemotherapy, 2010, 56(2), 147-152.
[http://dx.doi.org/10.1159/000313528] [PMID: 20407242]
[12]
Gaggin, H.K.; Truong, Q.A.; Rehman, S.U.; Mohammed, A.A.; Bhardwaj, A.; Parks, K.A.; Sullivan, D.A.; Chen-Tournoux, A.; Moore, S.A.; Richards, A.M.; Troughton, R.W.; Lainchbury, J.G.; Weiner, R.B.; Baggish, A.L.; Semigran, M.J.; Januzzi, J.L., Jr Characterization and prediction of natriuretic peptide “nonresponse” during heart failure management: results from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) and the NT-proBNP-Assisted Treatment to Lessen Serial Cardiac Readmissions and Death (BATTLESCARRED) study. Congest. Heart Fail., 2013, 19(3), 135-142.
[http://dx.doi.org/10.1111/chf.12016] [PMID: 23279139]
[13]
Fonarow, G.C.; Peacock, W.F.; Phillips, C.O.; Givertz, M.M.; Lopatin, M. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J. Am. Coll. Cardiol., 2007, 49(19), 1943-1950.
[http://dx.doi.org/10.1016/j.jacc.2007.02.037] [PMID: 17498579]
[14]
Cheng, V.; Kazanagra, R.; Garcia, A.; Lenert, L.; Krishnaswamy, P.; Gardetto, N.; Clopton, P.; Maisel, A. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J. Am. Coll. Cardiol., 2001, 37(2), 386-391.
[http://dx.doi.org/10.1016/S0735-1097(00)01157-8] [PMID: 11216951]
[15]
O’Brien, R.J.; Squire, I.B.; Demme, B.; Davies, J.E.; Ng, L.L. Pre-discharge, but not admission, levels of NT-proBNP predict adverse prognosis following acute LVF. Eur. J. Heart Fail., 2003, 5(4), 499-506.
[http://dx.doi.org/10.1016/S1388-9842(03)00098-9] [PMID: 12921811]
[16]
de Lemos, J.A.; McGuire, D.K.; Drazner, M.H. B-type natriuretic peptide in cardiovascular disease. Lancet, 2003, 362(9380), 316-322.
[http://dx.doi.org/10.1016/S0140-6736(03)13976-1] [PMID: 12892964]
[17]
Bettencourt, P.; Azevedo, A.; Pimenta, J.; Friões, F.; Ferreira, S.; Ferreira, A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation, 2004, 110(15), 2168-2174.
[http://dx.doi.org/10.1161/01.CIR.0000144310.04433.BE] [PMID: 15451800]
[18]
Doust, J.A.; Pietrzak, E.; Dobson, A.; Glasziou, P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ, 2005, 330(7492), 625.
[http://dx.doi.org/10.1136/bmj.330.7492.625] [PMID: 15774989]
[19]
van Kimmenade, R.R.; Januzzi, J.L., Jr Emerging biomarkers in heart failure. Clin. Chem., 2012, 58(1), 127-138.
[http://dx.doi.org/10.1373/clinchem.2011.165720] [PMID: 22086968]
[20]
Seronde, M.F.; Gayat, E.; Logeart, D.; Lassus, J.; Laribi, S.; Boukef, R.; Sibellas, F.; Launay, J.M.; Manivet, P.; Sadoune, M.; Nouira, S.; Solal, A.C.; Mebazaa, A. Comparison of the diagnostic and prognostic values of B-type and atrial-type natriuretic peptides in acute heart failure. Int. J. Cardiol., 2013, 168(4), 3404-3411.
[http://dx.doi.org/10.1016/j.ijcard.2013.04.164] [PMID: 23684562]
[21]
Masson, S.; Anand, I.; Favero, C.; Barlera, S.; Vago, T.; Bertocchi, F.; Maggioni, A.P.; Tavazzi, L.; Tognoni, G.; Cohn, J.N.; Latini, R. Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials. Circulation, 2012, 125(2), 280-288.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.111.044149] [PMID: 22139751]
[22]
Gravning, J.; Smedsrud, M.K.; Omland, T.; Eek, C.; Skulstad, H.; Aaberge, L.; Bendz, B.; Kjekshus, J.; Mørkrid, L.; Edvardsen, T. Sensitive troponin assays and N-terminal pro-B-type natriuretic peptide in acute coronary syndrome: prediction of significant coronary lesions and long-term prognosis. Am. Heart J., 2013, 165(5), 716-724.
[http://dx.doi.org/10.1016/j.ahj.2013.02.008] [PMID: 23622908]
[23]
Neumann, J.T.; Sörensen, N.A.; Schwemer, T.; Ojeda, F.; Bourry, R.; Sciacca, V.; Schaefer, S.; Waldeyer, C.; Sinning, C.; Renné, T.; Than, M.; Parsonage, W.; Wildi, K.; Makarova, N.; Schnabel, R.B.; Landmesser, U.; Mueller, C.; Cullen, L.; Greenslade, J.; Zeller, T.; Blankenberg, S.; Karakas, M.; Westermann, D. Diagnosis of Myocardial Infarction Using a High-Sensitivity Troponin I 1-Hour Algorithm. JAMA Cardiol., 2016, 1(4), 397-404.
[http://dx.doi.org/10.1001/jamacardio.2016.0695] [PMID: 27438315]
[24]
Everett, B.M.; Brooks, M.M.; Vlachos, H.E.; Chaitman, B.R.; Frye, R.L.; Bhatt, D.L. Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes. N. Engl. J. Med., 2015, 373(7), 610-620.
[http://dx.doi.org/10.1056/NEJMoa1415921] [PMID: 26267622]
[25]
Yancy, C.W.; Jessup, M.; Bozkurt, B.; Butler, J.; Casey, D.E., Jr; Drazner, M.H.; Fonarow, G.C.; Geraci, S.A.; Horwich, T.; Januzzi, J.L.; Johnson, M.R.; Kasper, E.K.; Levy, W.C.; Masoudi, F.A.; McBride, P.E.; McMurray, J.J.; Mitchell, J.E.; Peterson, P.N.; Riegel, B.; Sam, F.; Stevenson, L.W.; Tang, W.H.W.; Tsai, E.J.; Wilkoff, B.L. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation, 2013, 128(16), e240-e327.
[http://dx.doi.org/10.1161/CIR.0b013e31829e8776] [PMID: 23741058]
[26]
Eggers, K.M.; Lindahl, B. Application of cardiac troponin in cardiovascular diseases other than acute coronary syndrome. Clin. Chem., 2017, 63(1), 223-235.
[http://dx.doi.org/10.1373/clinchem.2016.261495] [PMID: 28062620]
[27]
Thygesen, K.; Alpert, J.S.; Jaffe, A.S.; Chaitman, B.R.; Bax, J.J.; Morrow, D.A.; White, H.D. Fourth universal definition of myocardial infarction (2018). J. Am. Coll. Cardiol., 2018, 72(18), 2231-2264.
[http://dx.doi.org/10.1016/j.jacc.2018.08.1038] [PMID: 30153967]
[28]
Weil, B.R.; Suzuki, G.; Young, R.F.; Iyer, V.; Canty, J.M., Jr Troponin Release and Reversible Left Ventricular Dysfunction After Transient Pressure Overload. J. Am. Coll. Cardiol., 2018, 71(25), 2906-2916.
[http://dx.doi.org/10.1016/j.jacc.2018.04.029] [PMID: 29929614]
[29]
Harrison, N.; Favot, M.; Levy, P. The Role of Troponin for Acute Heart Failure. Curr. Heart Fail. Rep., 2019, 16(1), 21-31.
[http://dx.doi.org/10.1007/s11897-019-0420-5] [PMID: 30762176]
[30]
Piper, H.M.; Schwartz, P.; Spahr, R.; Hütter, J.F.; Spieckermann, P.G. Early enzyme release from myocardial cells is not due to irreversible cell damage. J. Mol. Cell. Cardiol., 1984, 16(4), 385-388.
[http://dx.doi.org/10.1016/S0022-2828(84)80609-4] [PMID: 6726826]
[31]
Newby, L.K.; Jesse, R.L.; Babb, J.D.; Christenson, R.H.; De Fer, T.M.; Diamond, G.A.; Fesmire, F.M.; Geraci, S.A.; Gersh, B.J.; Larsen, G.C.; Kaul, S.; McKay, C.R.; Philippides, G.J.; Weintraub, W.S. ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations: a report of the American College of Cardiology Foundation task force on Clinical Expert Consensus Documents. J. Am. Coll. Cardiol., 2012, 60(23), 2427-2463.
[http://dx.doi.org/10.1016/j.jacc.2012.08.969] [PMID: 23154053]
[32]
Scott, D.L.; Ibrahim, F.; Farewell, V.; O’Keeffe, A.G.; Ma, M.; Walker, D.; Heslin, M.; Patel, A.; Kingsley, G. Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews. Health Technol. Assess., 2014, 18(66), i-xxiv, 1-164.
[http://dx.doi.org/10.3310/hta18660] [PMID: 25351370]
[33]
Clemens, R.K.; Annema, W.; Baumann, F.; Roth-Zetzsche, S.; Seifert, B.; von Eckardstein, A.; Amann-Vesti, B.R. Cardiac biomarkers but not measures of vascular atherosclerosis predict mortality in patients with peripheral artery disease. Clin. Chim. Acta, 2019, 495, 215-220.
[http://dx.doi.org/10.1016/j.cca.2019.04.061] [PMID: 30981846]
[34]
Ramkumar, N.; Jacobs, J.P.; Berman, R.B.; Parker, D.M.; MacKenzie, T.A.; Likosky, D.S.; DiScipio, A.; Malenka, D.J.; Brown, J.R. Cardiac biomarkers predict long-term survival after cardiac surgery. Ann. Thorac. Surg., 2019, 108(6), 1776-1782.
[http://dx.doi.org/10.1016/j.athoracsur.2019.04.123] [PMID: 31255614]
[35]
Niederdöckl, J.; Simon, A.; Schnaubelt, S.; Schuetz, N.; Laggner, R.; Sulzgruber, P.; Spiel, A.O.; Herkner, H.; Laggner, A.N.; Domanovits, H. Cardiac biomarkers predict mortality in emergency patients presenting with atrial fibrillation. Heart, 2019, 105(6), 482-488.
[http://dx.doi.org/10.1136/heartjnl-2018-313145] [PMID: 30415208]
[36]
Kreusser, M.M.; Geis, N.A.; Berlin, N.; Greiner, S.; Pleger, S.T.; Bekeredjian, R.; Katus, H.A.; Raake, P.W. Invasive hemodynamics and cardiac biomarkers to predict outcomes after percutaneous edge-to-edge mitral valve repair in patients with severe heart failure. Clin. Res. Cardiol., 2019, 108(4), 375-387.
[http://dx.doi.org/10.1007/s00392-018-1365-5] [PMID: 30191296]
[37]
Omland, T.; de Lemos, J.A.; Sabatine, M.S.; Christophi, C.A.; Rice, M.M.; Jablonski, K.A.; Tjora, S.; Domanski, M.J.; Gersh, B.J.; Rouleau, J.L.; Pfeffer, M.A.; Braunwald, E. A sensitive cardiac troponin T assay in stable coronary artery disease. N. Engl. J. Med., 2009, 361(26), 2538-2547.
[http://dx.doi.org/10.1056/NEJMoa0805299] [PMID: 19940289]
[38]
Peacock, W.F., IV; De Marco, T.; Fonarow, G.C.; Diercks, D.; Wynne, J.; Apple, F.S.; Wu, A.H. Cardiac troponin and outcome in acute heart failure. N. Engl. J. Med., 2008, 358(20), 2117-2126.
[http://dx.doi.org/10.1056/NEJMoa0706824] [PMID: 18480204]
[39]
Sato, Y.; Yamada, T.; Taniguchi, R.; Nagai, K.; Makiyama, T.; Okada, H.; Kataoka, K.; Ito, H.; Matsumori, A.; Sasayama, S.; Takatsu, Y. Persistently increased serum concentrations of cardiac troponin t in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes. Circulation, 2001, 103(3), 369-374.
[http://dx.doi.org/10.1161/01.CIR.103.3.369] [PMID: 11157687]
[40]
Antman, E.M.; Tanasijevic, M.J.; Thompson, B.; Schactman, M.; McCabe, C.H.; Cannon, C.P.; Fischer, G.A.; Fung, A.Y.; Thompson, C.; Wybenga, D.; Braunwald, E. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N. Engl. J. Med., 1996, 335(18), 1342-1349.
[http://dx.doi.org/10.1056/NEJM199610313351802] [PMID: 8857017]
[41]
Mair, J.; Genser, N.; Morandell, D.; Maier, J.; Mair, P.; Lechleitner, P.; Calzolari, C.; Larue, C.; Ambach, E.; Dienstl, F.; Pau, B.; Puschendorf, B. Cardiac troponin I in the diagnosis of myocardial injury and infarction. Clin. Chim. Acta, 1996, 245(1), 19-38.
[http://dx.doi.org/10.1016/0009-8981(95)06168-1] [PMID: 8646813]
[42]
Adams, J.E., III; Schechtman, K.B.; Landt, Y.; Ladenson, J.H.; Jaffe, A.S. Comparable detection of acute myocardial infarction by creatine kinase MB isoenzyme and cardiac troponin I. Clin. Chem., 1994, 40(7 Pt 1), 1291-1295.
[http://dx.doi.org/10.1093/clinchem/40.7.1291] [PMID: 8013101]
[43]
Missov, E.; Calzolari, C.; Pau, B. In Increased levels of cardiac troponin I in cancer patients, JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER SCIENCE INC 655 AVENUE OF THE AMERICAS. NEW YORK, NY, 1997, 10010, 15130-15130.
[44]
Löfberg, M.; Tähtelä, R.; Härkönen, M.; Somer, H. Cardiac troponins in severe rhabdomyolysis. Clin. Chem., 1996, 42(7), 1120-1121.
[http://dx.doi.org/10.1093/clinchem/42.7.1120a] [PMID: 8674206]
[45]
Lewis, W.R.; Amsterdam, E.A. Utility and safety of immediate exercise testing of low-risk patients admitted to the hospital for suspected acute myocardial infarction. Am. J. Cardiol., 1994, 74(10), 987-990.
[http://dx.doi.org/10.1016/0002-9149(94)90845-1] [PMID: 7977059]
[46]
Gomez, M.A.; Anderson, J.L.; Karagounis, L.A.; Muhlestein, J.B.; Mooers, F.B.; Group, R.S. An emergency department-based protocol for rapidly ruling out myocardial ischemia reduces hospital time and expense: results of a randomized study (ROMIO). J. Am. Coll. Cardiol., 1996, 28(1), 25-33.
[http://dx.doi.org/10.1016/0735-1097(96)00093-9] [PMID: 8752791]
[47]
Sanada, S.; Hakuno, D.; Higgins, L.J.; Schreiter, E.R.; McKenzie, A.N.; Lee, R.T. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J. Clin. Invest., 2007, 117(6), 1538-1549.
[http://dx.doi.org/10.1172/JCI30634] [PMID: 17492053]
[48]
Kakkar, R.; Lee, R.T. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat. Rev. Drug Discov., 2008, 7(10), 827-840.
[http://dx.doi.org/10.1038/nrd2660] [PMID: 18827826]
[49]
Veeraveedu, P.T.; Sanada, S.; Okuda, K.; Fu, H.Y.; Matsuzaki, T.; Araki, R.; Yamato, M.; Yasuda, K.; Sakata, Y.; Yoshimoto, T.; Minamino, T. Ablation of IL-33 gene exacerbate myocardial remodeling in mice with heart failure induced by mechanical stress. Biochem. Pharmacol., 2017, 138, 73-80.
[http://dx.doi.org/10.1016/j.bcp.2017.04.022] [PMID: 28450225]
[50]
Weir, R.A.; Miller, A.M.; Murphy, G.E.; Clements, S.; Steedman, T.; Connell, J.M.; McInnes, I.B.; Dargie, H.J.; McMurray, J.J. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J. Am. Coll. Cardiol., 2010, 55(3), 243-250.
[http://dx.doi.org/10.1016/j.jacc.2009.08.047] [PMID: 20117403]
[51]
Jenkins, W.S.; Roger, V.L.; Jaffe, A.S.; Weston, S.A.; AbouEzzeddine, O.F.; Jiang, R.; Manemann, S.M.; Enriquez-Sarano, M. Prognostic Value of Soluble ST2 After Myocardial Infarction: A Community Perspective. Am. J. Med., 2017, 130(9), 1112.e9-1112.e15.
[http://dx.doi.org/10.1016/j.amjmed.2017.02.034] [PMID: 28344136]
[52]
deFilippi, C.; Daniels, L.B.; Bayes-Genis, A. Structural heart disease and ST2: cross-sectional and longitudinal associations with echocardiography. Am. J. Cardiol., 2015, 115(7)(Suppl.), 59B-63B.
[http://dx.doi.org/10.1016/j.amjcard.2015.01.042] [PMID: 25702279]
[53]
Wang, Y.C.; Yu, C.C.; Chiu, F.C.; Tsai, C.T.; Lai, L.P.; Hwang, J.J.; Lin, J.L. Soluble ST2 as a biomarker for detecting stable heart failure with a normal ejection fraction in hypertensive patients. J. Card. Fail., 2013, 19(3), 163-168.
[http://dx.doi.org/10.1016/j.cardfail.2013.01.010] [PMID: 23482076]
[54]
Januzzi, J.L., Jr; Peacock, W.F.; Maisel, A.S.; Chae, C.U.; Jesse, R.L.; Baggish, A.L.; O’Donoghue, M.; Sakhuja, R.; Chen, A.A.; van Kimmenade, R.R.; Lewandrowski, K.B.; Lloyd-Jones, D.M.; Wu, A.H. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J. Am. Coll. Cardiol., 2007, 50(7), 607-613.
[http://dx.doi.org/10.1016/j.jacc.2007.05.014] [PMID: 17692745]
[55]
Shah, R.V.; Chen-Tournoux, A.A.; Picard, M.H.; van Kimmenade, R.R.; Januzzi, J.L. Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea. Circ Heart Fail, 2009, 2(4), 311-319.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.108.833707] [PMID: 19808354]
[56]
Anand, I.S.; Rector, T.S.; Kuskowski, M.; Snider, J.; Cohn, J.N. Prognostic value of soluble ST2 in the Valsartan Heart Failure Trial. Circ Heart Fail, 2014, 7(3), 418-426.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.113.001036] [PMID: 24622243]
[57]
Corre, J.; Hébraud, B.; Bourin, P. Concise review: growth differentiation factor 15 in pathology: a clinical role? Stem Cells Transl. Med., 2013, 2(12), 946-952.
[http://dx.doi.org/10.5966/sctm.2013-0055] [PMID: 24191265]
[58]
Kempf, T.; von Haehling, S.; Peter, T.; Allhoff, T.; Cicoira, M.; Doehner, W.; Ponikowski, P.; Filippatos, G.S.; Rozentryt, P.; Drexler, H.; Anker, S.D.; Wollert, K.C. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J. Am. Coll. Cardiol., 2007, 50(11), 1054-1060.
[http://dx.doi.org/10.1016/j.jacc.2007.04.091] [PMID: 17825714]
[59]
Baessler, A.; Strack, C.; Rousseva, E.; Wagner, F.; Bruxmeier, J.; Schmiedel, M.; Riegger, G.; Lahmann, C.; Loew, T.; Schmitz, G.; Fischer, M. Growth-differentiation factor-15 improves reclassification for the diagnosis of heart failure with normal ejection fraction in morbid obesity. Eur. J. Heart Fail., 2012, 14(11), 1240-1248.
[http://dx.doi.org/10.1093/eurjhf/hfs116] [PMID: 22843563]
[60]
Chan, M.M.; Santhanakrishnan, R.; Chong, J.P.; Chen, Z.; Tai, B.C.; Liew, O.W.; Ng, T.P.; Ling, L.H.; Sim, D.; Leong, K.T.G.; Yeo, P.S.; Ong, H.Y.; Jaufeerally, F.; Wong, R.C.; Chai, P.; Low, A.F.; Richards, A.M.; Lam, C.S. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction. Eur. J. Heart Fail., 2016, 18(1), 81-88.
[http://dx.doi.org/10.1002/ejhf.431] [PMID: 26497848]
[61]
Pareek, M.; Bhatt, D.L.; Vaduganathan, M.; Biering-Sørensen, T.; Qamar, A.; Diederichsen, A.C.; Møller, J.E.; Hindersson, P.; Leósdóttir, M.; Magnusson, M.; Nilsson, P.M.; Olsen, M.H. Single and multiple cardiovascular biomarkers in subjects without a previous cardiovascular event. Eur. J. Prev. Cardiol., 2017, 24(15), 1648-1659.
[http://dx.doi.org/10.1177/2047487317717065] [PMID: 28644092]
[62]
Hijazi, Z.; Verdecchia, P.; Oldgren, J.; Andersson, U.; Reboldi, G.; Di Pasquale, G.; Mazzotta, G.; Angeli, F.; Eikelboom, J.W.; Ezekowitz, M.D.; Connolly, S.J.; Yusuf, S.; Wallentin, L. Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE - LY Trial. J. Am. Heart Assoc., 2019, 8(2), e010107.
[http://dx.doi.org/10.1161/JAHA.118.010107] [PMID: 30651032]
[63]
Barondes, S.H.; Castronovo, V.; Cooper, D.N.; Cummings, R.D.; Drickamer, K.; Feizi, T.; Gitt, M.A.; Hirabayashi, J.; Hughes, C.; Kasai, K. Galectins: a family of animal beta-galactoside-binding lectins. Cell, 1994, 76(4), 597-598.
[http://dx.doi.org/10.1016/0092-8674(94)90498-7] [PMID: 8124704]
[64]
Anand, I.S.; Rector, T.S.; Kuskowski, M.; Adourian, A.; Muntendam, P.; Cohn, J.N. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Eur. J. Heart Fail., 2013, 15(5), 511-518.
[http://dx.doi.org/10.1093/eurjhf/hfs205] [PMID: 23291728]
[65]
Sharma, U.C.; Pokharel, S.; van Brakel, T.J.; van Berlo, J.H.; Cleutjens, J.P.; Schroen, B.; André, S.; Crijns, H.J.; Gabius, H.J.; Maessen, J.; Pinto, Y.M. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation, 2004, 110(19), 3121-3128.
[http://dx.doi.org/10.1161/01.CIR.0000147181.65298.4D] [PMID: 15520318]
[66]
Gehlken, C.; Suthahar, N.; Meijers, W.C.; de Boer, R.A. Galectin-3 in heart failure: an update of the last 3 years. Heart Fail. Clin., 2018, 14(1), 75-92.
[http://dx.doi.org/10.1016/j.hfc.2017.08.009] [PMID: 29153203]
[67]
Yu, L.; Ruifrok, W.P.; Meissner, M.; Bos, E.M.; van Goor, H.; Sanjabi, B.; van der Harst, P.; Pitt, B.; Goldstein, I.J.; Koerts, J.A.; van Veldhuisen, D.J.; Bank, R.A.; van Gilst, W.H.; Silljé, H.H.; de Boer, R.A. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail, 2013, 6(1), 107-117.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.112.971168] [PMID: 23230309]
[68]
de Boer, R.A.; Lok, D.J.; Jaarsma, T.; van der Meer, P.; Voors, A.A.; Hillege, H.L.; van Veldhuisen, D.J. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann. Med., 2011, 43(1), 60-68.
[http://dx.doi.org/10.3109/07853890.2010.538080] [PMID: 21189092]
[69]
Meijers, W.C.; Januzzi, J.L.; deFilippi, C.; Adourian, A.S.; Shah, S.J.; van Veldhuisen, D.J.; de Boer, R.A. Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials. Am. Heart J., 2014, 167(6), 853-60.e4.
[http://dx.doi.org/10.1016/j.ahj.2014.02.011] [PMID: 24890535]
[70]
Shah, R.V.; Chen-Tournoux, A.A.; Picard, M.H.; van Kimmenade, R.R.; Januzzi, J.L. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur. J. Heart Fail., 2010, 12(8), 826-832.
[http://dx.doi.org/10.1093/eurjhf/hfq091] [PMID: 20525986]
[71]
Minami, Y.; Kajimoto, K.; Sato, N.; Hagiwara, N.; Takano, T. C-reactive protein level on admission and time to and cause of death in patients hospitalized for acute heart failure. Eur. Heart J. Qual. Care Clin. Outcomes, 2017, 3(2), 148-156.
[PMID: 28927169]
[72]
Alonso-Martínez, J.L.; Llorente-Diez, B.; Echegaray-Agara, M.; Olaz-Preciado, F.; Urbieta-Echezarreta, M.; González-Arencibia, C. C-reactive protein as a predictor of improvement and readmission in heart failure. Eur. J. Heart Fail., 2002, 4(3), 331-336.
[http://dx.doi.org/10.1016/S1388-9842(02)00021-1] [PMID: 12034159]
[73]
Siirilä-Waris, K.; Lassus, J.; Melin, J.; Peuhkurinen, K.; Nieminen, M.S.; Harjola, V-P. Characteristics, outcomes, and predictors of 1-year mortality in patients hospitalized for acute heart failure. Eur. Heart J., 2006, 27(24), 3011-3017.
[http://dx.doi.org/10.1093/eurheartj/ehl407] [PMID: 17127708]
[74]
van Boven, N.; Akkerhuis, K.M.; Anroedh, S.S.; Battes, L.C.; Caliskan, K.; Yassi, W.; Manintveld, O.C.; Cornel, J.H.; Constantinescu, A.A.; Boersma, H.; Umans, V.A.; Kardys, I. In search of an efficient strategy to monitor disease status of chronic heart failure outpatients: added value of blood biomarkers to clinical assessment. Neth. Heart J., 2017, 25(11), 634-642.
[http://dx.doi.org/10.1007/s12471-017-1040-x] [PMID: 28983818]
[75]
Blankenberg, S.; Zeller, T.; Saarela, O.; Havulinna, A.S.; Kee, F.; Tunstall-Pedoe, H.; Kuulasmaa, K.; Yarnell, J.; Schnabel, R.B.; Wild, P.S. CLINICAL PERSPECTIVE. Circulation, 2010, 121(22), 2388-2397.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.109.901413] [PMID: 20497981]
[76]
Anand, I.S.; Latini, R.; Florea, V.G.; Kuskowski, M.A.; Rector, T.; Masson, S.; Signorini, S.; Mocarelli, P.; Hester, A.; Glazer, R.; Cohn, J.N. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation, 2005, 112(10), 1428-1434.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.104.508465] [PMID: 16129801]
[77]
Elliott, P.; Andersson, B.; Arbustini, E.; Bilinska, Z.; Cecchi, F.; Charron, P.; Dubourg, O.; Kühl, U.; Maisch, B.; McKenna, W.J.; Monserrat, L.; Pankuweit, S.; Rapezzi, C.; Seferovic, P.; Tavazzi, L.; Keren, A. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur. Heart J., 2008, 29(2), 270-276.
[http://dx.doi.org/10.1093/eurheartj/ehm342] [PMID: 17916581]
[78]
Brigden, W. Uncommon myocardial diseases: the non-coronary cardiomyopathies. Lancet, 1957, 273(7008), 1243-1249.
[http://dx.doi.org/10.1016/S0140-6736(57)91537-4] [PMID: 13492617]
[79]
Jenni, R.; Oechslin, E.N.; van der Loo, B. Isolated ventricular non-compaction of the myocardium in adults. Heart, 2007, 93(1), 11-15.
[http://dx.doi.org/10.1136/hrt.2005.082271] [PMID: 16670098]
[80]
Coats, C.J.; Heywood, W.E.; Mills, K.; Elliott, P.M. Current applications of biomarkers in cardiomyopathies. Expert Rev. Cardiovasc. Ther., 2015, 13(7), 825-837.
[http://dx.doi.org/10.1586/14779072.2015.1053873] [PMID: 26106935]
[81]
Mestroni, L.; Rocco, C.; Gregori, D.; Sinagra, G.; Di Lenarda, A.; Miocic, S.; Vatta, M.; Pinamonti, B.; Muntoni, F.; Caforio, A.L.; McKenna, W.J.; Falaschi, A.; Giacca, M.; Camerini, Familial dilated cardiomyopathy: evidence for genetic and phenotypic heterogeneity. J. Am. Coll. Cardiol., 1999, 34(1), 181-190.
[http://dx.doi.org/10.1016/S0735-1097(99)00172-2] [PMID: 10400009]
[82]
Hoogerwaard, E.M.; van der Wouw, P.A.; Wilde, A.A.; Bakker, E.; Ippel, P.F.; Oosterwijk, J.C.; Majoor-Krakauer, D.F.; van Essen, A.J.; Leschot, N.J.; de Visser, M. Cardiac involvement in carriers of Duchenne and Becker muscular dystrophy. Neuromuscul. Disord., 1999, 9(5), 347-351.
[http://dx.doi.org/10.1016/S0960-8966(99)00018-8] [PMID: 10407858]
[83]
Somer, H.; Dubowitz, V.; Donner, M. Creatine kinase isoenzymes in neuromuscular diseases. J. Neurol. Sci., 1976, 29(2-4), 129-136.
[http://dx.doi.org/10.1016/0022-510X(76)90165-9] [PMID: 978205]
[84]
Linhart, A.; Elliott, P.M. The heart in Anderson-Fabry disease and other lysosomal storage disorders. Heart, 2007, 93(4), 528-535.
[http://dx.doi.org/10.1136/hrt.2005.063818] [PMID: 17401074]
[85]
Weidemann, F.; Breunig, F.; Beer, M.; Sandstede, J.; Turschner, O.; Voelker, W.; Ertl, G.; Knoll, A.; Wanner, C.; Strotmann, J.M. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation, 2003, 108(11), 1299-1301.
[http://dx.doi.org/10.1161/01.CIR.0000091253.71282.04] [PMID: 12952834]
[86]
Rapezzi, C.; Arbustini, E.; Caforio, A.L.; Charron, P.; Gimeno-Blanes, J.; Heliö, T.; Linhart, A.; Mogensen, J.; Pinto, Y.; Ristic, A.; Seggewiss, H.; Sinagra, G.; Tavazzi, L.; Elliott, P.M. Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. Eur. Heart J., 2013, 34(19), 1448-1458.
[http://dx.doi.org/10.1093/eurheartj/ehs397] [PMID: 23211230]
[87]
Mehta, A.; Ricci, R.; Widmer, U.; Dehout, F.; Garcia de Lorenzo, A.; Kampmann, C.; Linhart, A.; Sunder-Plassmann, G.; Ries, M.; Beck, M. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur. J. Clin. Invest., 2004, 34(3), 236-242.
[http://dx.doi.org/10.1111/j.1365-2362.2004.01309.x] [PMID: 15025684]
[88]
Mantini, N.; Williams, B., Jr; Stewart, J.; Rubinsztain, L.; Kacharava, A. Cardiac sarcoid: a clinician’s review on how to approach the patient with cardiac sarcoid. Clin. Cardiol., 2012, 35(7), 410-415.
[http://dx.doi.org/10.1002/clc.21982] [PMID: 22499155]
[89]
Fløe, A.; Hoffmann, H.J.; Nissen, P.H.; Møller, H.J.; Hilberg, O. Genotyping increases the yield of angiotensin-converting enzyme in sarcoidosis--a systematic review. Dan. Med. J., 2014, 61(5), A4815.
[PMID: 24814734]
[90]
Kremastinos, D.T.; Farmakis, D. Iron overload cardiomyopathy in clinical practice. Circulation, 2011, 124(20), 2253-2263.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.111.050773] [PMID: 22083147]
[91]
Wood, J.C. History and current impact of cardiac magnetic resonance imaging on the management of iron overload. Circulation, 2009, 120(20), 1937-1939.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.109.907196] [PMID: 19884464]
[92]
Falk, R.H. Diagnosis and management of the cardiac amyloidoses. Circulation, 2005, 112(13), 2047-2060.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.104.489187] [PMID: 16186440]
[93]
Araújo, J.P.; Lourenço, P.; Azevedo, A.; Friões, F.; Rocha-Gonçalves, F.; Ferreira, A.; Bettencourt, P. Prognostic value of high-sensitivity C-reactive protein in heart failure: a systematic review. J. Card. Fail., 2009, 15(3), 256-266.
[http://dx.doi.org/10.1016/j.cardfail.2008.10.030] [PMID: 19327628]
[94]
Zimmermann, O.; Bienek-Ziolkowski, M.; Wolf, B.; Vetter, M.; Baur, R.; Mailänder, V.; Hombach, V.; Torzewski, J. Myocardial inflammation and non-ischaemic heart failure: is there a role for C-reactive protein? Basic Res. Cardiol., 2009, 104(5), 591-599.
[http://dx.doi.org/10.1007/s00395-009-0026-2] [PMID: 19343415]
[95]
Caforio, A.L.; Pankuweit, S.; Arbustini, E.; Basso, C.; Gimeno-Blanes, J.; Felix, S.B.; Fu, M.; Heliö, T.; Heymans, S.; Jahns, R.; Klingel, K.; Linhart, A.; Maisch, B.; McKenna, W.; Mogensen, J.; Pinto, Y.M.; Ristic, A.; Schultheiss, H.P.; Seggewiss, H.; Tavazzi, L.; Thiene, G.; Yilmaz, A.; Charron, P.; Elliott, P.M. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur. Heart J., 2013, 34(33), 2636-2648, 2648a-2648d.
[http://dx.doi.org/10.1093/eurheartj/eht210]
[96]
Lauer, B.; Niederau, C.; Kühl, U.; Schannwell, M.; Pauschinger, M.; Strauer, B-E.; Schultheiss, H-P. Cardiac troponin T in patients with clinically suspected myocarditis. J. Am. Coll. Cardiol., 1997, 30(5), 1354-1359.
[http://dx.doi.org/10.1016/S0735-1097(97)00317-3] [PMID: 9350939]
[97]
McMurray, J.J.; Adamopoulos, S.; Anker, S.D.; Auricchio, A.; Böhm, M.; Dickstein, K.; Falk, V.; Filippatos, G.; Fonseca, C.; Gomez-Sanchez, M.A.; Jaarsma, T.; Køber, L.; Lip, G.Y.; Maggioni, A.P.; Parkhomenko, A.; Pieske, B.M.; Popescu, B.A.; Rønnevik, P.K.; Rutten, F.H.; Schwitter, J.; Seferovic, P.; Stepinska, J.; Trindade, P.T.; Voors, A.A.; Zannad, F.; Zeiher, A. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. Heart J., 2012, 33(14), 1787-1847.
[http://dx.doi.org/10.1093/eurheartj/ehs104] [PMID: 22611136]
[98]
Sudoh, T.; Kangawa, K.; Minamino, N.; Matsuo, H. A new natriuretic peptide in porcine brain. Nature, 1988, 332(6159), 78-81.
[http://dx.doi.org/10.1038/332078a0] [PMID: 2964562]
[99]
Pieroni, M.; Bellocci, F.; Sanna, T.; Verardo, R.; Ierardi, C.; Maseri, A.; Frustaci, A.; Crea, F. Increased brain natriuretic peptide secretion is a marker of disease progression in nonobstructive hypertrophic cardiomyopathy. J. Card. Fail., 2007, 13(5), 380-388.
[http://dx.doi.org/10.1016/j.cardfail.2007.01.011] [PMID: 17602985]
[100]
Coats, C.J.; Gallagher, M.J.; Foley, M.; O’Mahony, C.; Critoph, C.; Gimeno, J.; Dawnay, A.; McKenna, W.J.; Elliott, P.M. Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy. Eur. Heart J., 2013, 34(32), 2529-2537.
[http://dx.doi.org/10.1093/eurheartj/eht070] [PMID: 23455360]
[101]
Geske, J.B.; McKie, P.M.; Ommen, S.R.; Sorajja, P. B-type natriuretic peptide and survival in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol., 2013, 61(24), 2456-2460.
[http://dx.doi.org/10.1016/j.jacc.2013.04.004] [PMID: 23602778]
[102]
Falk, R.H.; Dubrey, S.W. Amyloid heart disease. Amyloidosis; Springer, 2010, pp. 107-128.
[103]
Elliott, P.M.; Anastasakis, A.; Borger, M.A.; Borggrefe, M.; Cecchi, F.; Charron, P.; Hagege, A.A.; Lafont, A.; Limongelli, G.; Mahrholdt, H.; McKenna, W.J.; Mogensen, J.; Nihoyannopoulos, P.; Nistri, S.; Pieper, P.G.; Pieske, B.; Rapezzi, C.; Rutten, F.H.; Tillmanns, C.; Watkins, H. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur. Heart J., 2014, 35(39), 2733-2779.
[http://dx.doi.org/10.1093/eurheartj/ehu284] [PMID: 25173338]
[104]
Coats, C.J.; Parisi, V.; Ramos, M.; Janagarajan, K.; O’Mahony, C.; Dawnay, A.; Lachmann, R.H.; Murphy, E.; Mehta, A.; Hughes, D.; Elliott, P.M. Role of serum N-terminal pro-brain natriuretic peptide measurement in diagnosis of cardiac involvement in patients with anderson-fabry disease. Am. J. Cardiol., 2013, 111(1), 111-117.
[http://dx.doi.org/10.1016/j.amjcard.2012.08.055] [PMID: 23040658]
[105]
Cheng, H.; Lu, M.; Hou, C.; Chen, X.; Wang, J.; Yin, G.; Chu, J.; Zhang, S.; Prasad, S.K.; Pu, J.; Zhao, S. Relation between N-terminal pro-brain natriuretic peptide and cardiac remodeling and function assessed by cardiovascular magnetic resonance imaging in patients with arrhythmogenic right ventricular cardiomyopathy. Am. J. Cardiol., 2015, 115(3), 341-347.
[http://dx.doi.org/10.1016/j.amjcard.2014.10.040] [PMID: 25523952]
[106]
Kubo, T.; Kitaoka, H.; Yamanaka, S.; Hirota, T.; Baba, Y.; Hayashi, K.; Iiyama, T.; Kumagai, N.; Tanioka, K.; Yamasaki, N.; Matsumura, Y.; Furuno, T.; Sugiura, T.; Doi, Y.L. Significance of high-sensitivity cardiac troponin T in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol., 2013, 62(14), 1252-1259.
[http://dx.doi.org/10.1016/j.jacc.2013.03.055] [PMID: 23623916]
[107]
Taniguchi, R.; Sato, Y.; Nishio, Y.; Kimura, T.; Kita, T. Measurements of baseline and follow-up concentrations of cardiac troponin-T and brain natriuretic peptide in patients with heart failure from various etiologies. Heart Vessels, 2006, 21(6), 344-349.
[http://dx.doi.org/10.1007/s00380-006-0909-1] [PMID: 17143708]
[108]
Kitaoka, H.; Kubo, T.; Baba, Y.; Yamasaki, N.; Matsumura, Y.; Furuno, T.; Doi, Y.L. Serum tenascin-C levels as a prognostic biomarker of heart failure events in patients with hypertrophic cardiomyopathy. J. Cardiol., 2012, 59(2), 209-214.
[http://dx.doi.org/10.1016/j.jjcc.2011.11.008] [PMID: 22218323]
[109]
Rosenberg, M.; Zugck, C.; Nelles, M.; Juenger, C.; Frank, D.; Remppis, A.; Giannitsis, E.; Katus, H.A.; Frey, N. Osteopontin, a new prognostic biomarker in patients with chronic heart failure. Circ Heart Fail, 2008, 1(1), 43-49.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.107.746172] [PMID: 19808269]
[110]
Kristen, A.V.; Rosenberg, M.; Lindenmaier, D.; Merkle, C.; Steen, H.; Andre, F.; Schönland, S.O.; Schnabel, P.A.; Schuster, T.; Röcken, C.; Giannitsis, E.; Katus, H.A.; Frey, N. Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis. Amyloid, 2014, 21(3), 202-210.
[http://dx.doi.org/10.3109/13506129.2014.940457] [PMID: 25007036]
[111]
Yamamoto, M.; Hanatani, S.; Toshifumi, I.; Satoru, Y.; Kyoko, H.; Takashio, S.; Izumiya, Y.; Tsujita, K. Human epididymis protein 4 is a novel fibrosis marker to predict pathological cardiac remodeling and adverse outcomes in patients with dilated cardiomyopathy. J. Am. Coll. Cardiol., 2018, 71(11), A763.
[http://dx.doi.org/10.1016/S0735-1097(18)31304-4]
[112]
de la Porte, P.W.; Lok, D.J.; van Veldhuisen, D.J.; van Wijngaarden, J.; Cornel, J.H.; Zuithoff, N.P.; Badings, E.; Hoes, A.W. Added value of a physician-and-nurse-directed heart failure clinic: results from the Deventer-Alkmaar heart failure study. Heart, 2007, 93(7), 819-825.
[http://dx.doi.org/10.1136/hrt.2006.095810] [PMID: 17065182]
[113]
Radauceanu, A.; Ducki, C.; Virion, J-M.; Rossignol, P.; Mallat, Z.; McMurray, J.; Van Veldhuisen, D.J.; Tavazzi, L.; Mann, D.L.; Capiaumont-Vin, J.; Li, M.; Hanriot, D.; Zannad, F. Extracellular matrix turnover and inflammatory markers independently predict functional status and outcome in chronic heart failure. J. Card. Fail., 2008, 14(6), 467-474.
[http://dx.doi.org/10.1016/j.cardfail.2008.02.014] [PMID: 18672194]
[114]
Ochieng, J.; Furtak, V.; Lukyanov, P. Extracellular functions of galectin-3. Glycoconj. J., 2002, 19(7-9), 527-535.
[http://dx.doi.org/10.1023/B:GLYC.0000014082.99675.2f] [PMID: 14758076]
[115]
Liu, Y-H.; D’Ambrosio, M.; Liao, T-D.; Peng, H.; Rhaleb, N-E.; Sharma, U.; André, S.; Gabius, H-J.; Carretero, O.A. N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. Am. J. Physiol. Heart Circ. Physiol., 2009, 296(2), H404-H412.
[http://dx.doi.org/10.1152/ajpheart.00747.2008] [PMID: 19098114]
[116]
Lok, D.J.; Lok, S.I.; Bruggink-André de la Porte, P.W.; Badings, E.; Lipsic, E.; van Wijngaarden, J.; de Boer, R.A.; van Veldhuisen, D.J.; van der Meer, P. Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin. Res. Cardiol., 2013, 102(2), 103-110.
[http://dx.doi.org/10.1007/s00392-012-0500-y] [PMID: 22886030]
[117]
Clerico, A.; Iervasi, G.; Del Chicca, M.G.; Emdin, M.; Maffei, S.; Nannipieri, M.; Sabatino, L.; Forini, F.; Manfredi, C.; Donato, L. Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure. J. Endocrinol. Invest., 1998, 21(3), 170-179.
[http://dx.doi.org/10.1007/BF03347297] [PMID: 9591213]
[118]
Hulsmans, M.; Sager, H.B.; Roh, J.D.; Valero-Muñoz, M.; Houstis, N.E.; Iwamoto, Y.; Sun, Y.; Wilson, R.M.; Wojtkiewicz, G.; Tricot, B.; Osborne, M.T.; Hung, J.; Vinegoni, C.; Naxerova, K.; Sosnovik, D.E.; Zile, M.R.; Bradshaw, A.D.; Liao, R.; Tawakol, A.; Weissleder, R.; Rosenzweig, A.; Swirski, F.K.; Sam, F.; Nahrendorf, M. Cardiac macrophages promote diastolic dysfunction. J. Exp. Med., 2018, 215(2), 423-440.
[http://dx.doi.org/10.1084/jem.20171274] [PMID: 29339450]
[119]
Baldeviano, G.C.; Barin, J.G.; Talor, M.V.; Srinivasan, S.; Bedja, D.; Zheng, D.; Gabrielson, K.; Iwakura, Y.; Rose, N.R.; Cihakova, D. Interleukin-17A is dispensable for myocarditis but essential for the progression to dilated cardiomyopathy. Circ. Res., 2010, 106(10), 1646-1655.
[http://dx.doi.org/10.1161/CIRCRESAHA.109.213157] [PMID: 20378858]
[120]
Heidt, T.; Courties, G.; Dutta, P.; Sager, H.B.; Sebas, M.; Iwamoto, Y.; Sun, Y.; Da Silva, N.; Panizzi, P.; van der Laan, A.M.; Swirski, F.K.; Weissleder, R.; Nahrendorf, M. Differential contribution of monocytes to heart macrophages in steady-state and after myocardial infarction. Circ. Res., 2014, 115(2), 284-295.
[http://dx.doi.org/10.1161/CIRCRESAHA.115.303567] [PMID: 24786973]
[121]
Larsen, K.M.; Minaya, M.K.; Vaish, V.; Peña, M.M.O. The Role of IL-33/ST2 Pathway in Tumorigenesis. Int. J. Mol. Sci., 2018, 19(9), E2676.
[http://dx.doi.org/10.3390/ijms19092676] [PMID: 30205617]
[122]
Ghali, R.; Altara, R.; Louch, W.E.; Cataliotti, A.; Mallat, Z.; Kaplan, A.; Zouein, F.A.; Booz, G.W. IL-33 (Interleukin 33)/sST2 (Soluble Suppression of Tumorigenicity 2) axis in hypertension and heart failure. Hypertension, 2018, 72(4), 818-828.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.118.11157] [PMID: 30354724]
[123]
Tseng, C.C.S.; Huibers, M.M.H.; van Kuik, J.; de Weger, R.A.; Vink, A.; de Jonge, N. The interleukin-33/ST2 pathway is expressed in the failing human heart and associated with pro-fibrotic remodeling of the myocardium. J. Cardiovasc. Transl. Res., 2018, 11(1), 15-21.
[http://dx.doi.org/10.1007/s12265-017-9775-8] [PMID: 29285671]
[124]
Kempf, T.; Zarbock, A.; Widera, C.; Butz, S.; Stadtmann, A.; Rossaint, J.; Bolomini-Vittori, M.; Korf-Klingebiel, M.; Napp, L.C.; Hansen, B.; Kanwischer, A.; Bavendiek, U.; Beutel, G.; Hapke, M.; Sauer, M.G.; Laudanna, C.; Hogg, N.; Vestweber, D.; Wollert, K.C. GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat. Med., 2011, 17(5), 581-588.
[http://dx.doi.org/10.1038/nm.2354] [PMID: 21516086]
[125]
Adela, R.; Banerjee, S.K. GDF-15 as a target and biomarker for diabetes and cardiovascular diseases: a translational prospective. J. Diabetes Res., 2015, 2015, 490842.
[http://dx.doi.org/10.1155/2015/490842] [PMID: 26273671]
[126]
Lok, S.I.; Winkens, B.; Goldschmeding, R.; van Geffen, A.J.; Nous, F.M.; van Kuik, J.; van der Weide, P.; Klöpping, C.; Kirkels, J.H.; Lahpor, J.R.; Doevendans, P.A.; de Jonge, N.; de Weger, R.A. Circulating growth differentiation factor-15 correlates with myocardial fibrosis in patients with non-ischaemic dilated cardiomyopathy and decreases rapidly after left ventricular assist device support. Eur. J. Heart Fail., 2012, 14(11), 1249-1256.
[http://dx.doi.org/10.1093/eurjhf/hfs120] [PMID: 22843564]
[127]
Vegter, E.L.; van der Meer, P.; de Windt, L.J.; Pinto, Y.M.; Voors, A.A. MicroRNAs in heart failure: from biomarker to target for therapy. Eur. J. Heart Fail., 2016, 18(5), 457-468.
[http://dx.doi.org/10.1002/ejhf.495] [PMID: 26869172]
[128]
Devaux, Y.; Creemers, E.E.; Boon, R.A.; Werfel, S.; Thum, T.; Engelhardt, S.; Dimmeler, S.; Squire, I.; Network, C. Circular RNAs in heart failure. Eur. J. Heart Fail., 2017, 19(6), 701-709.
[http://dx.doi.org/10.1002/ejhf.801] [PMID: 28345158]
[129]
Watson, C.J.; Gupta, S.K.; O’Connell, E.; Thum, S.; Glezeva, N.; Fendrich, J.; Gallagher, J.; Ledwidge, M.; Grote-Levi, L.; McDonald, K.; Thum, T. MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure. Eur. J. Heart Fail., 2015, 17(4), 405-415.
[http://dx.doi.org/10.1002/ejhf.244] [PMID: 25739750]
[130]
Dickinson, B.A.; Semus, H.M.; Montgomery, R.L.; Stack, C.; Latimer, P.A.; Lewton, S.M.; Lynch, J.M.; Hullinger, T.G.; Seto, A.G.; van Rooij, E. Plasma microRNAs serve as biomarkers of therapeutic efficacy and disease progression in hypertension-induced heart failure. Eur. J. Heart Fail., 2013, 15(6), 650-659.
[http://dx.doi.org/10.1093/eurjhf/hft018] [PMID: 23388090]
[131]
Masson, S.; Batkai, S.; Beermann, J.; Bär, C.; Pfanne, A.; Thum, S.; Magnoli, M.; Balconi, G.; Nicolosi, G.L.; Tavazzi, L.; Latini, R.; Thum, T. Circulating microRNA-132 levels improve risk prediction for heart failure hospitalization in patients with chronic heart failure. Eur. J. Heart Fail., 2018, 20(1), 78-85.
[http://dx.doi.org/10.1002/ejhf.961] [PMID: 29027324]
[132]
Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi, W.; Lu, R.; Niu, P.; Zhan, F.; Ma, X.; Wang, D.; Xu, W.; Wu, G.; Gao, G.F.; Tan, W. A novel coronavirus from patients with pneumonia in China. N. Engl. J. Med., 2020, 382(8), 727-733.
[http://dx.doi.org/10.1056/NEJMoa2001017] [PMID: 31978945]
[133]
Dawson, D.; Dominic, P.; Sheth, A.; Modi, M. Prognostic value of Cardiac Biomarkers in COVID-19 Infection: A Meta-analysis. Res. Sq., 2020, rs.3.rs-34729..
[134]
Yang, X.; Yu, Y.; Xu, J.; Shu, H.; Xia, J.; Liu, H.; Wu, Y.; Zhang, L.; Yu, Z.; Fang, M.; Yu, T.; Wang, Y.; Pan, S.; Zou, X.; Yuan, S.; Shang, Y. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med., 2020, 8(5), 475-481.
[http://dx.doi.org/10.1016/S2213-2600(20)30079-5] [PMID: 32105632]
[135]
Fried, J.A.; Ramasubbu, K.; Bhatt, R.; Topkara, V.K.; Clerkin, K.J.; Horn, E.; Rabbani, L.; Brodie, D.; Jain, S.S.; Kirtane, A.J.; Masoumi, A.; Takeda, K.; Kumaraiah, D.; Burkhoff, D.; Leon, M.; Schwartz, A.; Uriel, N.; Sayer, G. The Variety of Cardiovascular Presentations of COVID-19. Circulation, 2020, 141(23), 1930-1936.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.120.047164] [PMID: 32243205]
[136]
Ahmed, S.I.; Khan, S. Coagulopathy and Plausible Benefits of Anticoagulation Among COVID-19 Patients. Curr. Probl. Cardiol., 2020, 45(9), 100648.
[http://dx.doi.org/10.1016/j.cpcardiol.2020.100648] [PMID: 32703535]
[137]
Sala, S.; Peretto, G.; Gramegna, M.; Palmisano, A.; Villatore, A.; Vignale, D.; De Cobelli, F.; Tresoldi, M.; Cappelletti, A.M.; Basso, C.; Godino, C.; Esposito, A. Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection. Eur. Heart J., 2020, 41(19), 1861-1862.
[http://dx.doi.org/10.1093/eurheartj/ehaa286] [PMID: 32267502]
[138]
Su, M.; Wang, Y.; Peng, J.; Wu, M.J.; Deng, W.; Yang, Y.S. Elevated cardiac biomarkers are associated with increased mortality for inpatients with COVID-19: A retrospective case-control study. J. Clin. Anesth., 2020, 65, 109894.
[http://dx.doi.org/10.1016/j.jclinane.2020.109894] [PMID: 32450473]
[139]
Sherwi, N.; Pellicori, P.; Joseph, A.C.; Buga, L. Old and newer biomarkers in heart failure: from pathophysiology to clinical significance. J. Cardiovasc. Med. (Hagerstown), 2013, 14(10), 690-697.
[http://dx.doi.org/10.2459/JCM.0b013e328361d1ef] [PMID: 23846675]
[140]
Jungbauer, C.G.; Riedlinger, J.; Block, D.; Stadler, S.; Birner, C.; Buesing, M.; König, W.; Riegger, G.; Maier, L.; Luchner, A. Panel of emerging cardiac biomarkers contributes for prognosis rather than diagnosis in chronic heart failure. Biomarkers Med., 2014, 8(6), 777-789.
[http://dx.doi.org/10.2217/bmm.14.31] [PMID: 25224934]
[141]
Velagaleti, R.S.; Gona, P.; Larson, M.G.; Wang, T.J.; Levy, D.; Benjamin, E.J.; Selhub, J.; Jacques, P.F.; Meigs, J.B.; Tofler, G.H.; Vasan, R.S. Multimarker approach for the prediction of heart failure incidence in the community. Circulation, 2010, 122(17), 1700-1706.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.109.929661] [PMID: 20937976]
[142]
Wang, T.J.; Wollert, K.C.; Larson, M.G.; Coglianese, E.; McCabe, E.L.; Cheng, S.; Ho, J.E.; Fradley, M.G.; Ghorbani, A.; Xanthakis, V.; Kempf, T.; Benjamin, E.J.; Levy, D.; Vasan, R.S.; Januzzi, J.L. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation, 2012, 126(13), 1596-1604.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.112.129437] [PMID: 22907935]
[143]
Zipes, D.P.; Libby, P.; Bonow, R.O.; Mann, D.L.; Tomaselli, G.F. Braunwald’s Heart Disease E-Book: A Textbook of Cardiovascular Medicine; Elsevier Health Sciences, 2018.
[144]
Mann, D.L.; Zipes, D.P.; Libby, P.; Bonow, R.O. Braunwald’s Heart Disease E-Book: A Textbook of Cardiovascular Medicine; Elsevier Health Sciences, 2014.